Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic oesophageal cancer: a JSMO–ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and T...

by Muro, Kei, Lordick, Florian, Tsushima, Takahiro, Pentheroudakis, George, Baba, Eishi, Lu, Zhihao, Cho, Byoung Chul, Nor, I.M., Ng, Matthew, Chen, Li Tzong, Kato, Ken, Li, Jin, Ryu, Min-hee, Wan Zamaniah, Wan Ishak, Yong, Wei Peng, Yeh, Kun Huei, Nakajima, Takako Eguchi, Shitara, Kouhei, Kawakami, Hisato, Narita, Yukiya, Yoshino, Takayuki, Van Cutsem, Eric, Martinelli, Erika, Smyth, Elizabeth C., Arnold, Dirk, Minami, Hironobu, Tabernero, J., Douillard, Jean Yves
Published 2019

Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer: a JSMO–ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS

by Muro, Kei, Van Cutsem, Eric, Narita, Yukiya, Pentheroudakis, George, Baba, Eishi, Li, Jin, Ryu, Min-hee, Wan Zamaniah, Wan Ishak, Yong, Wei Peng, Yeh, Kun Huei, Kato, Ken, Lu, Zhihao, Cho, Byoung Chul, Nor, I.M., Ng, Matthew, Chen, Li Tzong, Nakajima, Takako Eguchi, Shitara, Kouhei, Kawakami, Hisato, Tsushima, Takahiro, Yoshino, Takayuki, Lordick, Florian, Martinelli, Erika, Smyth, Elizabeth C., Arnold, Dirk, Minami, Hironobu, Tabernero, J., Douillard, Jean Yves
Published 2019

Olmutinib in T790M-positive non-small cell lung cancer after failure of first-line epidermal growth factor receptor-tyrosine kinase inhibitor therapy: A global, phase 2 study

by Park, Keunchil, Janne, Pasi A., Kim, Dong-Wan, Han, Ji-Youn, Wu, Ming-Fang, Lee, Jong-Seok, Kang, Jin-Hyoung, Lee, Dae Ho, Cho, Byoung Chul, Yu, Chong-Jen, Pang, Yong Kek, Felip, Enriqueta, Kim, Hyunjin, Baek, Eunhye, Noh, Young Su
Published 2021

Profiling of protein-protein interactions via single-molecule techniques predicts the dependence of cancers on growth-factor receptors

by Lee, Hong-Won, Choi, Byoungsan, Kang, Han Na, Kim, Hyunwoo, Min, Ahrum, Cha, Minkwon, Ryu, Ji Young, Park, Sangwoo, Sohn, Jinyoung, Shin, Kihyuk, Yun, Mi Ran, Han, Joo Yeun, Shon, Min Ju, Jeong, Cherlhyun, Chung, Junho, Lee, Seung-Hyo, Im, Seock-Ah, Cho, Byoung Chul, Yoon, Tae-Young]
Published 2022

Repotrectinib (TPX-0005) is a next-generation ROS1/TRK/ALK inhibitor that potently inhibit ROS1/TRK/ALK solvent-front mutations

by Drilon, Alexander, Ou, Sai-Hong Ignatius, Cho, Byoung Chul, Kim, Dong-Wan, Lees, Jeeyun, Lin, Jessica J., Zhu, Viola W., Ahns, Myung-Ju, Camidge, D. Ross, Nguyen, Judy, Zhai, Dayong, Deng, Wei, Huang, Zhongdong, Rogers, Evan, Liu, Juliet, Whitten, Jeff, Lim, John K., Stopatschinskaja, Shanna, Hyman, David M., Doebele, Robert C., Cui, J. Jean, Shaw, Alice T.
Published 2020

A multicenter phase II study of everolimus in patients with progressive unresectable adenoid cystic carcinoma

by Kim, Dong-Wan, Oh, Do-Youn, Shin, Seong Hoon, Kang, Jin Hyoung, Cho, Byoung Chul, Chung, Joo-Seop, Kim, HyeJin, Park, Keon Uk, Kwon, Jung Hye, Han, Ji-Youn, Kim, Mi-Jung, Bang, Yung-Jue
Published 2020

Phase 2 study of dovitinib in patients with metastatic or unresectable adenoid cystic carcinoma

by Keam, Bhumsuk, Kim, Sung-Bae, Shin, Seong Hoon, Cho, Byoung Chul, Lee, Keun-Wook, Kim, Min Kyoung, Yun, Hwan-Jung, Lee, Se-Hoon, Yoon, Dok Hyun, Bang, Yung-Jue
Published 2021

Phase Ib/II study of the pan-cyclin-dependent kinase inhibitor roniciclib in combination with chemotherapy in patients with extensive-disease small-cell lung cancer

by Cho, Byoung Chul, Dy, Grace K., Govindan, Ramaswamy, Kim, Dong-Wan, Pennell, Nathan A., Zalcman, Gerard, Besse, Benjamin, Kim, Joo-Hang, Koca, Goekben, Rajagopalan, Prabhu, Langer, Simon, Ocker, Matthias, Nogai, Hendrik, Barlesi, Fabrice
Published 2020

Impact of a planned dose interruption of dacomitinib in the treatment of advanced non-small-cell lung cancer (ARCHER 1042)

by Kim, Dong-Wan, Garon, Edward B., Jatoi, Aminah, Keefe, Dorothy M., Lacouture, Mario E., Sonis, Stephen, Gernhardt, Diana, Wang, Tao, Giri, Nagdeep, Doherty, Jim P., Nadanaciva, Sashi, O'Connell, Joseph, Sbar, Eric, Cho, Byoung Chul
Published 2020

A randomized, phase II study of gefitinib alone versus nimotuzumab plus gefitinib after platinum-based chemotherapy in advanced non-small cell lung cancer (KCSG LU12-01)

by Kim, Hye Ryun, Jang, Joung Soon, Sun, Jong-Mu, Ahn, Myung-Ju, Kim, Dong-Wan, Jung, Inkyung, Lee, Ki Hyeong, Kim, Joo-Hang, Lee, Dae Ho, Kim, Sang-We, Cho, Byoung Chul
Published 2020

A multicenter phase II study of sorafenib in combination with erlotinib in patients with advanced non-small cell lung cancer (KCSG-0806)

by Lim, Sun Min, Cho, Byoung Chul, Kim, Sang-We, Kang, Seok Yun, Heo, Dae Seog, Kim, Heung Tae, Lee, Dae Ho, Kim, Dong-Wan, Jung, Minkyu, Choi, Jin-Hyuk, Shim, Hyo Sup, Choi, Jong Rak, Kim, Joo-Hang
Published 2020

Real-World Experience of Nivolumab in Non-small Cell Lung Cancer in Korea

by Lim, Sun Min, Kim, Sang-We, Cho, Byoung Chul, Kang, Jin Hyung, Ahn, Myung-Ju, Kim, Dong-Wan, Kim, Young-Chul, Lee, Jin Soo, Lee, Jong-Seok, Lee, Sung Yong, Park, Keon Uk, An, Ho Jung, Cho, Eun Kyung, Jang, Tae Won, Kim, Bong-Seog, Kim, Joo-Hang, Lee, Sung Sook, Na, Im-Ii, Yoo, Seung Soo, Lee, Ki Hyeong
Published 2021

Osimertinib in Patients with T790M-Positive Advanced Non-small Cell Lung Cancer: Korean Subgroup Analysis from Phase II Studies

by Ahn, Myung-Ju, Han, Ji-Youn, Kim, Dong-Wan, Cho, Byoung Chul, Kang, Jin-Hyoung, Kim, Sang-We, Yang, James Chih-Hsin, Mitsudomi, Tetsuya, Lee, Jong Seok
Published 2021

Real-world use of osimertinib in non-small cell lung cancer: ASTRIS study Korean subgroup analysis

by Cho, Byoung Chul, Kim, Dong-Wan, Park, Keunchil, Lee, Jong Seok, Yoo, Seung Soo, Kang, Jin Hyoung, Lee, Sung Yong, Kim, Cheol Hyeon, Jang, Seung Hun, Kim, Young-Chul, Yoon, Hyoung-Kyu, Han, Ji-Youn, Kim, Sang-We
Published 2020

Osimertinib in patients with epidermal growth factor receptor mutation-positive non-small-cell lung cancer and leptomeningeal metastases: The BLOOM study

by Yang, James C. H., Kim, Sang-We, Kim, Dong-Wan, Lee, Jong-Seok, Cho, Byoung Chul, Ahn, Jin-Seok, Lee, Dae H., Kim, Tae Min, Goldman, Jonathan W., Natale, Ronald B., Brown, Andrew P., Collins, Barbara, Chmielecki, Juliann, Vishwanathan, Karthick, Mendoza-Naranjo, Ariadna, Ahn, Myung-Ju
Published 2021

Nivolumab in advanced non-small-cell lung cancer patients who failed prior platinum-based chemotherapy

by Lee, Jong Seok, Lee, Ki Hyeong, Cho, Eun Kyung, Kim, Dong-Wan, Kim, Sang-We, Kim, Joo-Hang, Cho, Byoung Chul, Kang, Jin Hyoung, Han, Ji-Youn, Min, Young Joo, Park, Keunchil
Published 2020

ASCEND-8: A randomized phase 1 study of ceritinib, 450 mg or 600 mg, taken with a low-fat meal versus 750 mg in fasted state in patients with anaplastic lymphoma kinase (ALK)-rearr...

by Cho, Byoung Chul, Kim, Dong-Wan, Bearz, Alessandra, Laurie, Scott A., McKeage, Mark, Borra, Gloria, Park, Keunchil, Kim, Sang-We, Ghosn, Marwan, Ardizzoni, Andrea, Maiello, Evaristo, Greystoke, Alastair, Yu, Richard, Osborne, Karen, Gu, Wen, Scott, Jeffrey W., Passos, Vanessa Q., Lau, Yvonne Y., Wrona, Anna
Published 2020

Safety, tolerability, and anti-tumor activity of olmutinib in non-small cell lung cancer with T790M mutation: A single arm, open label, phase 1/2 trial

by Kim, Dong-Wan, Lee, Dae Ho, Han, Ji-Youn, Lee, Jong Seok, Cho, Byoung Chul, Kang, Jin Hyoung, Lee, Ki Hyeong, Cho, Eun Kyung, Kim, Jin-Soo, Min, Young Joo, Cho, Jae Yong, An, Ho Jung, Kim, Hoon-Gu, Lee, Kyung Hee, Kim, Bong-Seog, Jang, In-Jin, Yoon, Seonghae, Han, OakPil, Noh, Young Su, Hong, Ka Young, Park, Keunchil
Published 2020

Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1-Positive Advanced NSCLC

by Herbst, Roy S., Garon, Edward B., Kim, Dong-Wan, Cho, Byoung Chul, Gervais, Radj, Perez-Gracia, Jose L., Han, Ji-Youn, Majem, Margarita, Forster, Martin D., Monnet, Isabelle, Novello, Silvia, Gubens, Matthew A., Boyer, Michael, Su, Wu-Chou, Samkari, Ayman, Jensen, Erin H., Kobie, Julie, Piperdi, Bilal, Baas, Paul
Published 2022

Anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody quavonlimab in combination with pembrolizumab: Safety and efficacy from a phase I study in previously treated e...

by Cho, Byoung Chul, Yoh, Kiyotaka, Perets, Ruth, Nagrial, Adnan, Spigel, David R., Gutierrez, Martin, Kim, Dong-Wan, Kotasek, Dusan, Rasco, Drew, Niu, Jiaxin, Satouchi, Miyako, Ahn, Myung-Ju, Lee, Dae Ho, Maurice-Dror, Corinne, Siddiqi, Shabana, Ren, Yixin, Altura, Rachel A., Bar, Jair
Published 2022